Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.

Ganapathy A, Nieves JW, Keaveny TM, Cosman F

Bone21 Nov 2022Cited by 10 (Europe PMC)

PMID36410666PMCIDPMC9822869DOI10.1016/j.bone.2022.116618PepBankPUB-36410666

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, spine integral vBMD gains did not differ significantly between two years daily and four years cyclic teriparatide.
In plain wordsIn postmenopausal women, spine density gains were similar with two years daily versus four years cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSpine integral vBMD
Study
n: not reported in source
Comparator
Four years cyclic teriparatide
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily or cyclically · 2 years daily vs 4 years cyclicAs given in this study (human).
Measurements
vBMD change
12%
Daily
vBMD change
11%
Cyclic
Source sentences
Summary
In the spine, integral vBMD and strength increased substantially after 2 years daily and 4 years cyclic TPTD, with no significant differences (vBMD +12 % vs +11 %, respectively, p = 0.70; spine strength +21 % vs +16 %, respectively, p = 0.35).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 86 women were randomized to a 24-month open label treatment of either daily TPTD (20 μg daily) or cyclic TPTD (20 μg daily for 3 months followed by 3 months off).
Summary · context
The primary analysis presented here compared the responses across equal total TPTD doses (2 years daily vs 4 years cyclic).
Report a problemFND-3641066601
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, spine strength gains did not differ significantly between two years daily and four years cyclic teriparatide.
In plain wordsIn postmenopausal women, spine strength gains were similar with two years daily versus four years cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSpine strength
Study
n: not reported in source
Comparator
Four years cyclic teriparatide
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily or cyclically · 2 years daily vs 4 years cyclicAs given in this study (human).
Measurements
Strength change
21%
Daily
Strength change
16%
Cyclic
Source sentences
Summary
In the spine, integral vBMD and strength increased substantially after 2 years daily and 4 years cyclic TPTD, with no significant differences (vBMD +12 % vs +11 %, respectively, p = 0.70; spine strength +21 % vs +16 %, respectively, p = 0.35).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 86 women were randomized to a 24-month open label treatment of either daily TPTD (20 μg daily) or cyclic TPTD (20 μg daily for 3 months followed by 3 months off).
Summary · context
The primary analysis presented here compared the responses across equal total TPTD doses (2 years daily vs 4 years cyclic).
Report a problemFND-3641066602
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, hip vBMD gains did not differ significantly between two years daily and four years cyclic teriparatide.
In plain wordsIn postmenopausal women, hip density gains were similar with two years daily versus four years cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHip vBMD
Study
n: not reported in source
Comparator
Four years cyclic teriparatide
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily or cyclically · 2 years daily vs 4 years cyclicAs given in this study (human).
Measurements
vBMD change
2%
Both groups
Source sentences
Summary
At the hip, the gains were smaller, but again no significant differences were detected between the groups for the increases in either vBMD (+2 % in both groups, p = 0.97) or hip strength (3 % vs 3 %, p = 0.91).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 86 women were randomized to a 24-month open label treatment of either daily TPTD (20 μg daily) or cyclic TPTD (20 μg daily for 3 months followed by 3 months off).
Summary · context
The primary analysis presented here compared the responses across equal total TPTD doses (2 years daily vs 4 years cyclic).
Report a problemFND-3641066603
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, hip strength gains did not differ significantly between two years daily and four years cyclic teriparatide.
In plain wordsIn postmenopausal women, hip strength gains were similar with two years daily versus four years cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHip strength
Study
n: not reported in source
Comparator
Four years cyclic teriparatide
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily or cyclically · 2 years daily vs 4 years cyclicAs given in this study (human).
Measurements
Strength change
3%
Both groups
Source sentences
Summary
At the hip, the gains were smaller, but again no significant differences were detected between the groups for the increases in either vBMD (+2 % in both groups, p = 0.97) or hip strength (3 % vs 3 %, p = 0.91).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 86 women were randomized to a 24-month open label treatment of either daily TPTD (20 μg daily) or cyclic TPTD (20 μg daily for 3 months followed by 3 months off).
Summary · context
The primary analysis presented here compared the responses across equal total TPTD doses (2 years daily vs 4 years cyclic).
Report a problemFND-3641066604
05HumanNon-randomized trialEfficacy outcome
In postmenopausal women receiving teriparatide, significant hip vBMD gain occurred only in the trabecular compartment.
In plain wordsIn postmenopausal women receiving teriparatide, significant hip density gain occurred only in the trabecular compartment.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedHip compartment vBMD gain
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily or cyclicallyAs given in this study (human).
Source sentences
Summary
In the spine, the vBMD increment was about twice as large in the trabecular vs peripheral compartment; in the hip, significant vBMD gain was seen only in the trabecular compartment.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 86 women were randomized to a 24-month open label treatment of either daily TPTD (20 μg daily) or cyclic TPTD (20 μg daily for 3 months followed by 3 months off).
Summary · context
The primary analysis presented here compared the responses across equal total TPTD doses (2 years daily vs 4 years cyclic).
Report a problemFND-3641066606

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In postmenopausal women receiving teriparatide, the spine vBMD increment was about twice as large in the trabecular as peripheral compartment.
In plain wordsIn postmenopausal women receiving teriparatide, spine density increased more in the trabecular compartment than the peripheral compartment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine compartment vBMD increment
Study
n: not reported in source
Comparator
Peripheral compartment
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the spine, the vBMD increment was about twice as large in the trabecular vs peripheral compartment; in the hip, significant vBMD gain was seen only in the trabecular compartment.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 86 women were randomized to a 24-month open label treatment of either daily TPTD (20 μg daily) or cyclic TPTD (20 μg daily for 3 months followed by 3 months off).
Summary · context
The primary analysis presented here compared the responses across equal total TPTD doses (2 years daily vs 4 years cyclic).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3641066605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT00668941

Cyclic Versus Daily Teriparatide on Bone Mass

Helen Hayes Hospitaln = 140Sept 2005 to est. Nov 2017

Osteoporosis

Trial page ClinicalTrials.govUpdated 10 Aug 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.